COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

LOWER: Lomitapide Observational Worldwide Evaluation Registry (LOWER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02135705
Recruitment Status : Enrolling by invitation
First Posted : May 12, 2014
Last Update Posted : December 15, 2017
Information provided by (Responsible Party):
Aegerion Pharmaceuticals, Inc.

Brief Summary:
This global product exposure registry is a multicentre, long-term, prospective, observational cohort study (exposure registry), designed to evaluate the long term safety and effectiveness of lomitapide.

Condition or disease Intervention/treatment
Homozygous Familial Hypercholesterolemia Drug: Lomitapide

Detailed Description:
To evaluate the occurrence of adverse events of special interest, long term effectiveness of lomitapide, and to evaluate whether prescribers of lomitapide are following screening and monitoring recommendations as specified in product labeling.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 300 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 10 Years
Official Title: LOWER: Lomitapide Observational Worldwide Evaluation Registry
Study Start Date : March 2014
Estimated Primary Completion Date : March 2028
Estimated Study Completion Date : September 2028

Resource links provided by the National Library of Medicine

Drug Information available for: Lomitapide

Group/Cohort Intervention/treatment
Lomitapide as prescribed by Physician.
Drug: Lomitapide
As prescribed by Physician.
Other Names:
  • Juxtapid
  • Lojuxta

Primary Outcome Measures :
  1. Hepatic Abnormalities [ Time Frame: patients will be followed for 10 years ]
    to evaluate the occurrence of hepatic abnormalities

Secondary Outcome Measures :
  1. Gastrointestinal (GI) Events [ Time Frame: patients will be followed for 10 years ]
    to evaluate the occurrence of GI events

  2. Tumors [ Time Frame: patients will be followed for 10 years ]
    to evaluate any occurrence of tumors (small bowel, hepatic, colorectal or pancreatic)

  3. Events associated with coagulopathy [ Time Frame: patients will be followed for 10 years ]
    to evaluate the occurrence of events associated with coagulopathy (abnormal bleeding, cerebral haemorrhage or GI bleeding)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult patients treated with lomitapide who agree to participate in the study.

Inclusion Criteria:

  • Adult patients (age ≥18 years) who meet one of the following two criteria:

Initiating treatment with lomitapide at the time of registry enrolment, or initiated treatment with lomitapide within 15 months prior to enrolment into the registry and after lomitapide commercial availability in the country.

  • Patients who have the ability to understand the requirements of the study and provide written informed consent to comply with the study data collection procedures.

Exclusion Criteria:

  • Patients who are receiving lomitapide in clinical trials
  • Patients receiving an investigational agent, defined as any drug or biologic agent other than lomitapide that has not received MA in the country of participation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02135705

Layout table for location information
United States, Michigan
Complete Family Care
Sterling Heights, Michigan, United States, 48314
Sponsors and Collaborators
Aegerion Pharmaceuticals, Inc.
Additional Information:

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Aegerion Pharmaceuticals, Inc. Identifier: NCT02135705    
Other Study ID Numbers: AEGR-733-025
First Posted: May 12, 2014    Key Record Dates
Last Update Posted: December 15, 2017
Last Verified: December 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Hyperlipoproteinemia Type II
Lipid Metabolism Disorders
Metabolic Diseases
Lipid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn